The Current Status of Photodynamic Therapy in Cancer Treatment

Cancers, Год журнала: 2023, Номер 15(3), С. 585 - 585

Опубликована: Янв. 18, 2023

Although we have made great strides in treating deadly diseases over the years, cancer therapy still remains a daunting challenge. Among numerous anticancer methods, photodynamic (PDT), non-invasive therapeutic approach, has attracted much attention. PDT exhibits outstanding performance therapy, but some unavoidable disadvantages, including limited light penetration depth, poor tumor selectivity, as well oxygen dependence, largely limit its efficiency for solid tumors treatment. Thus, strategies gone into overcoming these obstacles, such exploring new photosensitizers with higher conversion efficiency, alleviating hypoxia to fuel generation of reactive species (ROS), designing tumor-targeted PS, and applying PDT-based combination strategies. In this review, briefly summarized related approaches, which are mainly characterized by advanced PSs, PSs excellent additional refreshing features. We also summarize therapies effects.

Язык: Английский

---

Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy

Journal of Controlled Release, Год журнала: 2022, Номер 352, С. 793 - 812

Опубликована: Ноя. 11, 2022

Язык: Английский

---

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Theranostics, Год журнала: 2023, Номер 13(5), С. 1520 - 1544

Опубликована: Янв. 1, 2023

Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on forms of various regulating mechanisms to enhance therapeutic effect, including blockade interaction between PD-1, downregulation expression degradation mature PD-L1. Thereinto, describe variety materials been designed target PD-L1, antibodies, nanoparticle, peptide, aptamer, RNA, small molecule. Additionally, list drugs regulation capacity used in clinical ongoing studies explore other alternatives besides anti-PD-L1 monoclonal antibodies. Moreover, discuss associated opportunities cancer combination therapy modalities such as chemotherapy, radiotherapy, photodynamic (PDT) photothermal (PTT), these conventional or emerging capable increasing cells by altering microenvironment (TME), would display synergistic effect. At last, give brief summary outlook regarding research status future prospect immunotherapy.

Язык: Английский

---

Hydrogel systems for targeted cancer therapy

Frontiers in Bioengineering and Biotechnology, Год журнала: 2023, Номер 11

Опубликована: Фев. 16, 2023

When hydrogel materials with excellent biocompatibility and biodegradability are used as new drug carriers in the treatment of cancer, they confer following three advantages. First, can be a precise controlled release systems, which continuously sequentially chemotherapeutic drugs, radionuclides, immunosuppressants, hyperthermia agents, phototherapy agents other substances widely cancer through radiotherapy, chemotherapy, immunotherapy, hyperthermia, photodynamic therapy photothermal therapy. Second, have multiple sizes delivery routes, targeted to different locations types cancer. This greatly improves targeting thereby reducing dose drugs improving effectiveness. Finally, intelligently respond environmental changes according internal external stimuli so that anti-cancer active remotely released on demand. Combining abovementioned advantages, transformed into hit field treatment, bringing hope further increase survival rate quality life patients

Язык: Английский

---

Metabolic Intervention Liposome Boosted Lung Cancer Radio‐Immunotherapy via Hypoxia Amelioration and PD‐L1 Restraint

Advanced Science, Год журнала: 2023, Номер 10(18)

Опубликована: Апрель 24, 2023

At present, radiotherapy (RT) still acquires limited success in clinical due to the lessened DNA damage under hypoxia and acquired immune tolerance owing amplified programmed death ligand-1 (PD-L1) expression. Incredibly, intracellular PD-L1 expression depression is proven better sensitize RT by inhibiting repair. However, disability of clinically used antibodies disrupting extracellular PD-L1function limits effectiveness radio-immunotherapy. Therefore, regulation strategies are urgently needed Hence, for this purpose, TPP-LND synthesized linking mitochondrial-targeted triphenylphosphine cations (TPP+ ) antineoplastic agent lonidamine (LND), which significantly reduces dose LND induce effective oxidative phosphorylation inhibition (2 vs 300 µM). Then, wrapped with liposomes form TPP-LND@Lip nanoparticles. By doing this, nanoparticles can reversing hypoxic microenvironment tumors generate more reducing via enhancing adenosine 5'-monophosphate-activated protein kinase activation. As expected, these well-designed economical than conventional anti-PD-L1 some extent.

Язык: Английский

---

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Advanced Science, Год журнала: 2023, Номер 10(18)

Опубликована: Апрель 23, 2023

Dendritic cell (DC)-based cancer immunotherapy has exhibited remarkable clinical prospects because DCs play a central role in initiating and regulating adaptive immune responses. However, the application of traditional DC-mediated is limited due to insufficient antigen delivery, inadequate presentation, high levels immunosuppression. To address these challenges, engineered biomaterials have been exploited enhance immunotherapeutic effects. In this review, vital principal components that can effects are first introduced. The parameters considered rational design biomaterials, including targeting modifications, size, shape, surface, mechanical properties, which affect biomaterial optimization DC functions, further summarized. Moreover, recent applications various field reviewed, those serve as component delivery platforms, remodel tumor microenvironment, synergistically other antitumor therapies. Overall, present review comprehensively systematically summarizes related promotion functions; specifically focuses on advances designs for activation eradicate tumors. challenges opportunities treatment strategies designed amplify via discussed with aim inspiring translation future immunotherapies.

Язык: Английский

---

Light-Triggered Nanozymes Remodel the Tumor Hypoxic and Immunosuppressive Microenvironment for Ferroptosis-Enhanced Antitumor Immunity

ACS Nano, Год журнала: 2024, Номер 18(19), С. 12261 - 12275

Опубликована: Апрель 29, 2024

Cancer immunotherapy holds significant promise for addressing diverse malignancies. Nevertheless, its efficacy remains constrained by the intricate tumor immunosuppressive microenvironment. Herein, a light-triggered nanozyme Fe-TCPP-R848-PEG (Fe-MOF-RP) was designed remodeling The Fe-TCPP-MOFs were utilized not only as core catalysis component against destruction but also biocompatible delivery vector of an immunologic agonist, improving long circulation and enrichment. Concurrently, it catalyzes decomposition H2O2 within tumor, yielding oxygen to augment photodynamic therapy. induced ferroptosis, in synergy with therapy, prompts liberation tumor-associated antigens from cells inducing immunogenic cell death. Phototriggered on-demand release R848 agonists stimulated maturation dendritic reverted tumor-promoting M2 phenotypes into adoptive M1 macrophages, which further reshaped Notably, effectively restrains well-established tumors, such B16F10 melanoma. Moreover, demonstrates distal tumor-inhibiting effect upon situ light treatment. What is more, lung metastasis model, elicits robust immune memory, conferring enduring protection rechallenge. Our study presents straightforward broadly applicable strategy crafting nanozymes potential thwart cancer recurrence metastasis.

Язык: Английский

---

Remote Control of Energy Transformation‐Based Cancer Imaging and Therapy

Advanced Materials, Год журнала: 2024, Номер 36(27)

Опубликована: Март 29, 2024

Cancer treatment requires precise tumor-specific targeting at specific sites that allows for high-resolution diagnostic imaging and long-term patient-tailorable cancer therapy; while, minimizing side effects largely arising from non-targetability. This can be realized by harnessing exogenous remote stimuli, such as tissue-penetrative ultrasound, magnetic field, light, radiation, enable local activation therapy in deep tumors. A myriad of nanomedicines efficiently activated when the energy stimuli transformed into another type energy. review discusses control transformation targetable, efficient, therapy. Such ultrasonic, magnetic, photonic, radiative, radioactive mechanical, thermal, chemical, radiative to a variety modalities. The current article describes multimodal where serial cascade or multiple types occur. includes not only hyperthermia, radiation but also emerging thermoelectric, pyroelectric, piezoelectric therapies treatment. It illustrates resonance, fluorescence, computed tomography, photoluminescence, photoacoustic imaging-guided therapies. highlights afterglow eliminate autofluorescence sustained signal emission after excitation.

Язык: Английский

---

The use of photodynamic therapy in medical practice

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Май 8, 2024

Cancer therapy, especially for tumors near sensitive areas, demands precise treatment. This review explores photodynamic therapy (PDT), a method leveraging photosensitizers (PS), specific wavelength light, and oxygen to target cancer effectively. Recent advancements affirm PDT’s efficacy, utilizing ROS generation induce cell death. With history spanning over decades, dynamic evolution has expanded its application across dermatology, oncology, dentistry. aims dissect principles, from inception contemporary medical applications, highlighting role in modern treatment strategies.

Язык: Английский

---

Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis

Advanced Science, Год журнала: 2024, Номер 11(26)

Опубликована: Май 7, 2024

Abstract Currently, the typical combination therapy of programmed death ligand‐1 (PD‐L1) antibodies with radiotherapy (RT) still exhibits impaired immunogenic antitumor response in clinical due to lessened DNA damage and acquired immune tolerance via upregulation some other checkpoint inhibitors. Apart from this, such may raise occurrence rate radiation‐induced lung fibrosis (RIPF) enhanced systemic inflammation, leading ultimate cancer patients (average survival time about 3 years). Therefore, it is newly revealed that mitochondria energy metabolism regulation can be used as a novel effective PD‐L1 transforming growth factor‐β (TGF‐β) dual‐downregulation method. Following IR‐TAM prepared by conjugating mitochondria‐targeted heptamethine cyanine dye IR‐68 oxidative phosphorylation (OXPHOS) inhibitor Tamoxifen (TAM), which then self‐assembled albumin (Alb) form IR‐TAM@Alb nanoparticles. By doing tumor‐targeting nanoparticle effectively reversed tumor hypoxia depressed TGF‐β expression sensitize RT. Meanwhile, capacity targeting RIPF function TAM depressing TGF‐β, also ameliorated development induced

Язык: Английский

---